Why the study?
As the use of sutureless aortic valves has increased over the past decade, valve degeneration is increasingly encountered, prompting the need to describe clinical outcomes and technical aspects of valve-in-valve transcatheter aortic valve replacement for degenerated Perceval bioprostheses.
Is valve-in-valve transcatheter aortic valve replacement safe and effective in patients with degenerated Perceval bioprosthesis?
Is valve-in-valve transcatheter aortic valve replacement safe and effective in patients with degenerated Perceval bioprosthesis?
VIV-TAVR appears to be a safe and effective treatment option for patients with degenerated Perceval sutureless aortic bioprostheses, yielding 100% survival and good hemodynamic performance at 16 months.
May support VIV-TAVR for degenerated Perceval valves; hypothesis-generating and requires prospective validation.
BACKGROUND: Sutureless aortic bioprostheses are increasingly being used to provide shorter cross-clamp time and facilitate minimally invasive aortic valve replacement. As the use of sutureless valves has increased over the past decade, we begin to encounter their degeneration. We describe clinical outcomes and technical aspects in patients with degenerated sutureless Perceval (CorCym, Italy) aortic bioprosthesis treated with valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). METHODS: Between March 2011 and March 2023, 1310 patients underwent aortic valve replacement (AVR) with Perceval bioprosthesis implantation. Severe bioprosthesis degeneration treated with VIV-TAVR occurred in 32 patients with a mean of 6.4 ± 1.9 years (range: 2-10 years) after first implantation. Mean EuroSCORE II was 9.5 ± 6.4% (range: 1.9-35.1%). RESULTS: Thirty of thirty-two (94%) VIV-TAVR were performed via transfemoral and two (6%) via transapical approach. Vascular complications occurred in two patients (6%), and mean hospital stay was 4.6 ± 2.4 days. At mean follow-up of 16.7 ± 15.2 months (range: 1-50 months), survival was 100%, and mean transvalvular pressure gradient was 18.7 ± 5.3 mmHg. CONCLUSION: VIV-TAVR is a useful option for degenerated Perceval and appears safe and effective. This procedure is associated with good clinical results and excellent hemodynamic performance in our largest single-center experience.
No takes yet. Share an insight, caveat, or question.
Concistrè et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: